Close Menu

NEW YORK (GenomeWeb) – Veracyte said today that it has signed an agreement with Quest Diagnostics that will broaden access to the Afirma Gene Expression Classifier (GEC), a laboratory-developed test used to resolve indeterminate results on fine-needle-aspiration biopsies that were initially evaluated by cytopathology for potential thyroid cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.